Table .
Baseline Characteristics for Participants With CCTA Measurements Stratified by ASCVD Category
| Variable | All participants (N=662), mean (SD) | ASCVD risk 0% to <5% (n=368), mean (SD) | ASCVD risk 5%–7.5% (n=162), mean (SD) | ASCVD risk >7.5% (n=130), mean (SD) | P value |
|---|---|---|---|---|---|
| Age, y | 50.9 (5.8) | 48.6 (4.7) | 52.5 (5.5) | 55.1 (5.8) | <0.0001 |
| Body mass index, kg/m2 | 27.2 (4.4) | 27.3 (4.4) | 27.1 (4.0) | 27.4 (4.7) | 0.515 |
| Total years smoked | 21.5 (12.2) | 19.1 (11.0) | 21.1 (11.7) | 26.3 (13.7) | <0.0001 |
| CD4 count, cells/mm3 | 628.9 (268.9) | 633.1 (278.5) | 624.1 (259.8) | 623.2 (253.9) | 0.984 |
| eGFR, mL/min | 88.7 (16.4) | 89.4 (16.1) | 88.5 (16.3) | 86.8 (17.0) | 0.123 |
| LDL‐C concentration, mg/dL | 107.4 (30.3) | 106.2 (30.1) | 111.8 (32.5) | 105.8 (27.8) | 0.977 |
| HDL‐C concentration, mg/dL | 50.1 (17.7) | 52.4 (17.7) | 48.0 (19.4) | 46.2 (14.6) | 0.0008 |
| Triglyceride concentration, mg/dL | 134.3 (83.4) | 124.3 (73.5) | 146.5 (97.5) | 147.7 (87.4) | 0.0037 |
| Glucose concentration, mg/dL | 93.0 (12.1) | 92.2 (12.2) | 92.8 (11.6) | 95.4 (12.4) | 0.0078 |
| Variable | All participants, n/N (%) | ASCVD risk 0% to <5%, n/N (%) | ASCVD risk 5%–7.5%, n/N (%) | ASCVD risk >7.5%, n/N (%) |
|---|---|---|---|---|
| Sex | ||||
| Female | 106/660 (16.1) | 90/368 (24.5) | 13/162 (8) | 3/130 (2.3) |
| Male | 554/660 (83.9) | 278/368 (75.5) | 149/162 (92) | 127/130 (97.7) |
| Ancestry | ||||
| African | 277/662 (41.8) | 129/368 (35.1) | 70/162 (43.2) | 77/130 (59.2) |
| European | 379/662 (57.3) | 234/368 (63.6) | 92/162 (56.8) | 52/130 (40) |
| East Asian | 6/662 (0.9) | 5/368 (1.4) | 0/162 (0) | 1/130 (0.8) |
| South Asian | 1/662 (0.2) | 0/368 (0) | 0/162 (0) | 0/130 (0) |
| Hypertension | 206/662 (31.1) | 79/368 (21.5) | 52/162 (32.1) | 75/130 (57.7) |
| Physical activity | ||||
| Poor | 220/655 (33.6) | 117/364 (32.1) | 54/161 (33.5) | 49/130 (37.7) |
| Intermediate | 357/655 (54.5) | 205/364 (56.3) | 84/161 (52.2) | 68/130 (52.3) |
| Ideal | 78/655 (11.9) | 42/364 (11.5) | 23/161 (14.3) | 13/130 (10) |
| Diet | ||||
| Poor | 179/659 (27.2) | 92/368 (25) | 49/162 (30.2) | 38/129 (29.5) |
| Intermediate | 355/659 (53.9) | 192/368 (52.2) | 89/162 (54.9) | 74/129 (57.4) |
| Ideal | 125/659 (19) | 84/368 (22.8) | 24/162 (14.8) | 17/129 (13.2) |
| Plaque characteristics | ||||
| Any plaque | 325/660 (49.2) | 147/368 (39.9) | 91/162 (56.2) | 87/130 (66.9) |
| Stenosis >50% | 24/650 (3.7) | 7/366 (1.9) | 8/159 (5) | 9/125 (7.2) |
| Calcified plaque | 117/660 (17.7) | 45/368 (12.2) | 34/162 (21) | 38/130 (29.2) |
| Plaque with vulnerable features | 153/660 (23.2) | 66/368 (17.9) | 38/162 (23.5) | 49/130 (37.7) |
| Low‐attenuation plaque | 40/660 (6.1) | 13/368 (3.5) | 10/162 (6.2) | 17/130 (13.1) |
| Partially calcified plaque | 229/660 (34.7) | 104/368 (28.3) | 66/162 (40.7) | 59/130 (45.4) |
| Noncalcified plaque | 73/660 (11.1) | 35/368 (9.5) | 20/162 (12.3) | 18/130 (13.8) |
| Visible noncalcified plaque segments | 268/660 (40.6) | 123/368 (33.4) | 77/162 (47.5) | 68/130 (52.3) |
| Visible noncalcified plaque or plaque with vulnerable features | 282/660 (42.7) | 132/368 (35.9) | 79/162 (48.8) | 71/130 (54.6) |
| Napkin‐ring sign | 22/660 (3.3) | 6/368 (1.6) | 5/162 (3.1) | 11/130 (8.5) |
| Plaque present | 325/660 (49.2) | 147/368 (39.9) | 91/162 (56.2) | 87/130 (66.9) |
| Positive remodeling | 149/660 (22.6) | 65/368 (17.7) | 37/162 (22.8) | 47/130 (36.2) |
Table of baseline characteristics for 662 participants with CCTA measurements, including stratification, into ASCVD tertiles (0% to <5%, 5%–7.5%, and >7.5%). The top section of baseline characteristics (rows Age to Triglyceride concentration) lists the mean (SD) value among all participants, in addition to stratification by ASCVD tertiles. P value corresponds to Student's t test between <5% and >7.5% ASCVD risk cohorts. The bottom section of baseline characteristics (rows Sex to Plaque characteristics) counts the number of participants in each variable subcategory among all participants, in addition to stratification by ASCVD tertiles. ASCVD indicates atherosclerotic cardiovascular disease; CCTA, coronary computed tomography angiography; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; and LDL‐C, low‐density lipoprotein cholesterol.